BioXpress Therapeutics SA

28/07/2016

Partnership Agreement

BioXpress Therapeutics SA closed its sixth partnership agreement. This agreement extends the partnership with a Southeast Asia Partner to enable access to oncology drugs at throughout Southeast Asia at a reasonable cost.

BioXpress

17/09/2014

Biosimilar mAbs to cut Europe's healthcare bill by €20bn by 2020

At present Biosimilars save Europe roughly €2.40 per person, or €1.8bn a year, but by 2020 follow-on mAbs alone will shave €20bn off the continent’s healthcare bill according to researchers.

05/09/2014

The Biotech Lobby Fights To Undermine Less-Costly Biosimilar Drugs

By IKE BRANNON: Companies want to make more money for their shareholders, and there’s nothing wrong with that. But an effort to inhibit competition, done in the guise of protecting the consumer when it’s doing nothing of the sort should be recognized by the FDA for what it is.

19/08/2014

Lilly-Boehringer's biosimilar insulin gets tentative approval from FDA

Subject to automatic stay of up to 30 months because of court battle

16/08/2014

BioXpress Therapeutics conducts complete analytical comparison of the product to determine the therapeutic is similar to the innovator product.

12/08/2014

US Biosimilar News > Celltrion submits first biosimilar mAb application to FDA

Celltrion submits first biosimilar mAb application to FDA

03/08/2014

After months of debate and uncertainty, the World Health Organization has released a proposal for naming biosimilars, which are designed to emulate brand-name biologics and are forecast to save untold billions of dollars in health care costs in coming years.

15/06/2011

BioXpress Therapeutics SA is a privately held biotechnology committed to developing and supplying the highest quality and cost-competitive biosimilar biologic API for unmet need indications such as cancer, inflammation and autoimmunity.

BioXpress Therapeutics to Meet with Companies Interested in Monoclonal Antibody Biosimilars